This study confirms the efficacy of pembrolizumab in the treatment of advanced NSCLC with high PD-L1 expression, highlighting its potential to provide better outcomes and improved tolerability compared to conventional chemotherapy [4]. Here, CD274 is linked to non-small cell lung carcinoma.